Cardiovascular burden prior to diagnosis of hereditary transthyretin-mediated amyloidosis

P1101

  • Llonch, M V
  • Ortiz-Perez, J T
  • Reddy, S R
  • Chang, E
  • Tarbox, Marian MH
  • Pollock, M R
  • Nativi-Nicolau, J
  • Fine, N M

  • 1Akcea Therapeutics, Boston, United States of America

    2Hospital Clinic de Barcelona, Amyloidosis and Myeloma Unit, Barcelona, Spain

    3Partnership for Health Analytic Research, LLC, Beverly Hills, United States of America

    4University of Utah, School of Medicine, Salt Lake City, United States of America

    5University of Calgary, Calgary, Canada

European Journal of Heart Failure 22:p 173-174, September 2020.
Copyright © 2020 European Society of Cardiology
View full text|Download PDF